Your Rod Cells Hold One Million
Molecules of Rhodopsin.
Without Vitamin A, They're Useless.
Night blindness is a symptom, not a disease. In India it is usually Vitamin A deficiency — entirely reversible with the right food or a single dose of supplementation. But it can also mean retinitis pigmentosa, glaucoma, or a medication side effect. This is the complete guide to understanding which.
subclinical VAD globally
(adults, ICMR India)
night blindness
prevents it
Night blindness (nyctalopia) is the inability to see well in dim light or darkness. It is a symptom, not a disease. The main causes in India: Vitamin A deficiency (most common, preventable, reversible), retinitis pigmentosa (hereditary, progressive, currently incurable), cataracts, glaucoma, high myopia, and zinc deficiency. Vitamin A is essential for producing rhodopsin — the photopigment in rod cells that enables vision in low light. Without enough Vitamin A, rhodopsin cannot regenerate after light bleaching. Treatment by cause: VAD → oral Vitamin A supplementation (WHO protocol: 200,000 IU age ≥1 year) + dietary improvement (sweet potato, carrots, dark leafy greens, liver, eggs); cataracts → surgery; RP → no cure currently, low-vision aids, vitamin supplementation slows progression. Best preventive foods in India: sweet potato/shakarkand, carrot, drumstick leaves (moringa), spinach, methi, eggs, ghee. Children aged 9–59 months should receive Vitamin A supplements every 6 months under the National Programme.
Rhodopsin: The Only Molecule
Standing Between You and Total Darkness
The human retina contains two types of photoreceptors: approximately 6 million cones — concentrated in the central macula, responsible for colour and fine detail in bright light — and approximately 120 million rods, distributed across the peripheral retina, responsible for low-light (scotopic) vision. At night, in a dimly lit room, or in a cinema, it is almost entirely your rod cells that are working.
Each rod outer segment contains roughly 1,000 disc membranes, each packed with approximately 1,000 molecules of rhodopsin — a G-protein coupled receptor consisting of a protein (opsin) covalently bound to a chromophore (11-cis-retinal). 11-cis-retinal is a derivative of Vitamin A (retinol). When a single photon of light strikes a rhodopsin molecule, 11-cis-retinal isomerises to all-trans-retinal — this conformational change triggers a cascade of G-protein signalling that hyperpolarises the rod cell and transmits a visual signal to the optic nerve.
After bleaching (light exposure), all-trans-retinal must be converted back to 11-cis-retinal to regenerate functional rhodopsin — a process called the visual cycle. This regeneration occurs in the retinal pigment epithelium (RPE) and depends critically on a constant supply of Vitamin A. If Vitamin A is deficient, rhodopsin cannot regenerate after bleaching. The result: rod function is impaired in low light, and the person cannot see in the dark — night blindness.
This is why night blindness from Vitamin A deficiency is fully reversible: replenish the Vitamin A supply, regenerate the rhodopsin, and rod function returns. No permanent structural damage has occurred — unless the deficiency progresses to corneal disease (xerophthalmia, keratomalacia).
ROD vs CONE — SCOTOPIC vs PHOTOPIC VISION COMPARISON
Night blindness is a rod cell problem. Rods contain rhodopsin — the single photopigment that requires Vitamin A. Cones (colour vision, daytime) use different opsins and are largely unaffected by Vitamin A deficiency until severe depletion occurs.
"Rhodopsin constitutes approximately 85% of the total protein content of the rod outer segment disc membrane. Its photoisomerisation by a single photon initiates a signal amplification cascade sufficient to generate a measurable electrical response — this extraordinary sensitivity is what allows the human eye to detect a candle flame at over a mile in darkness, but only if the rhodopsin reservoir is full."
— Adapted from Lamb TD, Pugh EN Jr. "Dark adaptation and the retinoid cycle of vision." Prog Retin Eye Res. 2004.Night Blindness Is a Symptom.
Here Are the Six Things That Cause It.
Vitamin A Deficiency
Rhodopsin cannot regenerate without Vitamin A. Night blindness is the earliest functional sign of VAD — appearing before any structural eye damage. Common in children under 5 and pregnant/lactating women with poor dietary intake. Fully reversible with supplementation.
Retinitis Pigmentosa
Hereditary rod-cone dystrophy: rod cells progressively degenerate. Night blindness is usually the first symptom (teens–30s), followed by progressive peripheral visual field loss, then central vision loss in later stages. Currently incurable. ~1 in 3,000–4,000 people globally.
Cataracts
Lens clouding reduces total light transmission. Pupils dilate in dim light — a cloudy lens in dim light scatters more light proportionally than in bright conditions. Night driving difficulty is a common early cataract symptom. Fully reversible with cataract surgery. See our Cataract Surgery guide.
Glaucoma
Advanced glaucoma destroys peripheral retinal ganglion cells — and rods are densest in the peripheral retina. As glaucoma advances, the scotopic (night) field shrinks before the photopic (day) field because peripheral rod loss reduces dim-light peripheral vision. Night driving restriction is an important quality-of-life issue in advanced glaucoma.
High Myopia
Uncorrected or high myopia reduces the clarity of dim-light images due to retinal defocus. Pupil dilation in dim light increases the diameter of the circle of confusion from an uncorrected refractive error — worsening low-light visual acuity. Correcting myopia (glasses, contact lenses) substantially improves night vision in this group.
Zinc Deficiency
Zinc is required for the synthesis of retinol-binding protein (RBP) in the liver — the transport protein that carries Vitamin A to the retina. In zinc-deficient patients, even adequate dietary Vitamin A may not reach the retina effectively. Zinc deficiency is common in India, particularly in children with malnutrition. Co-supplementation of zinc with Vitamin A improves outcomes better than Vitamin A alone in zinc-deficient populations.
India's Night Blindness:
Preventable. Persistent. Unaddressed.
receiving Vit A supplements (NFHS-5)
prevents night blindness
and mortality risk in children
supplement in national programme
India's National Programme for Prevention and Control of Blindness (NPCB) includes Vitamin A supplementation for children aged 9 months to 5 years — one dose every 6 months. Despite this, NFHS-5 (2019–21) data shows only 59.8% of targeted children received their last supplement dose. In tribal, rural, and low-income urban populations, the coverage gap is wider.
The specific burden in India's context:
- Pregnant women — VAD in pregnant women causes night blindness (a marker of VAD severity) and impairs fetal Vitamin A stores. Night blindness in pregnant women in India is a sentinel indicator for VAD requiring immediate intervention.
- Breastfeeding women — breast milk is the primary Vitamin A source for infants. VAD in lactating mothers means Vitamin A-deficient breast milk, directly transmitting deficiency to the infant.
- Children with diarrhoea or measles — acute illness depletes Vitamin A rapidly. WHO recommends Vitamin A supplementation during measles treatment in developing countries — including India — because measles dramatically worsens VAD and vice versa.
- Malabsorption conditions — Vitamin A is a fat-soluble vitamin; conditions causing fat malabsorption (chronic diarrhoea, celiac disease, biliary obstruction, cystic fibrosis, bariatric surgery) impair Vitamin A absorption regardless of dietary intake.
The 2025 awareness study from Himachal Pradesh confirms the core gap: while 82% of surveyed adults could identify night blindness, only 61.5% knew Vitamin A could prevent it — meaning even people who recognise the condition cannot act on prevention effectively. This awareness gap is the primary target for public health education campaigns.
VITAMIN A SUPPLEMENTATION COVERAGE — INDIA REGIONAL VARIATION (NFHS-5)
Source: NFHS-5 (2019–21), proportion of children 9–59 months who received a Vitamin A supplement in the last 6 months. Significant inter-state variation reflects differential programme implementation and access.
When VAD Gets Worse:
The Xerophthalmia Progression
Night blindness is the earliest functional sign of Vitamin A deficiency — but if the deficiency is not corrected, progressive ocular damage follows. The WHO classifies VAD ocular manifestations using the Xerophthalmia staging system (Sommer, 1982):
XEROPHTHALMIA STAGING — WHO CLASSIFICATION (SOMMER 1982)
Night blindness (XN) is Stage 1. Treatment at this stage produces complete recovery. Keratomalacia (X3) — corneal melting from severe VAD — causes permanent scarring and blindness. Bitot's spots (X1B) are foamy, triangular conjunctival deposits adjacent to the limbus — a classic clinical sign of VAD, visible at the slit lamp or with a torch.
X3 xerophthalmia (keratomalacia) — corneal softening and necrosis from severe prolonged VAD — is a medical emergency. A malnourished child presenting with keratomalacia requires immediate high-dose Vitamin A (200,000 IU orally on Day 1, Day 2, and Day 14 per WHO protocol) plus systemic nutritional support, antibiotic eye drops, and urgent ophthalmology referral. Corneal perforation can occur within hours in severe cases. Permanent corneal scarring and blindness result even with treatment at this stage. Any paediatric patient with measles, diarrhoea, or malnutrition and corneal signs should be treated presumptively for VAD immediately — do not wait for serum retinol results.
How Much Vitamin A
Are You Actually Getting Today?
When Night Blindness Is Not Vitamin A:
Retinitis Pigmentosa
Retinitis pigmentosa (RP) is a group of inherited retinal dystrophies characterised by progressive rod photoreceptor degeneration, followed by cone degeneration. It is the most common hereditary cause of blindness, affecting approximately 1 in 3,500–4,000 people globally — and is the dominant cause of non-nutritional night blindness in India.
RP presents as a clinical triad:
- Night blindness — typically the first symptom, appearing in the second or third decade of life. Rod cells in the peripheral retina degenerate first, so dim-light and peripheral vision are initially affected.
- Progressive peripheral visual field loss — "tunnel vision." As rods continue to die, the visual field constricts from the periphery inward. At advanced stages, the patient may have central vision only, as if looking through a narrow tube.
- Eventual central vision loss — as cone degeneration follows rod degeneration in later stages, central visual acuity also declines. Full blindness occurs in some but not all patients.
On examination, the classic fundus signs of RP include:
- Bone-spicule pigmentation in the mid-peripheral retina — dark, branching pigment deposits resembling bone spicules on slit-lamp biomicroscopy
- Waxy pallor of the optic disc
- Attenuation of retinal blood vessels
- Reduced or extinguished ERG (electroretinogram) — the definitive diagnostic test
Genetics: RP can be autosomal dominant (ADRP), autosomal recessive (ARRP), or X-linked (XLRP — most severe, affects males, carrier females sometimes symptomatic). Over 80 causative genes have been identified. In India, consanguineous marriages (particularly in some communities) increase the prevalence of autosomal recessive RP.
Management: Currently, there is no approved cure for most forms of RP. Vitamin A palmitate supplementation (15,000 IU/day) has shown modest slowing of ERG decline in some trials (Berson et al., 1993) but remains controversial. Luxturna (voretigene neparvovec) — an AAV2-mediated gene therapy for RPE65 mutation-associated retinal dystrophy — is approved and available, but RPE65 mutations represent only ~1% of RP cases. Low-vision rehabilitation, orientation and mobility training, and adaptive technology are the primary support for most RP patients. Bright light avoidance and UV-protective spectacles are recommended to slow cone degeneration. Regular retinal follow-up is essential.
What the Doctor Finds:
From Torch to Electroretinogram
Night blindness diagnosis begins with distinguishing between the common, reversible causes (Vitamin A deficiency, cataracts, uncorrected myopia) and the rarer but serious hereditary and structural causes (RP, advanced glaucoma, medication toxicity). The workup:
- Clinical history — onset (sudden vs gradual), age, family history of night blindness or blindness, dietary history (VAD risk factors), medications (chloroquine, hydroxychloroquine, anti-epileptics), systemic conditions (malabsorption, bariatric surgery, IBD)
- Visual acuity and refraction — uncorrected myopia as a contributing factor
- Dilated fundus examination with TRIDILATE — to assess the lens (cataract), optic disc (glaucoma, RP pallor), macula (AMD, chorioretinal atrophy), and peripheral retina (RP bone-spicule pigmentation, choroidal changes)
- Slit-lamp examination with FLUROSCÉNE strips for corneal staining — evaluating corneal status (xerosis, Bitot spots, early keratomalacia), conjunctival xerosis, and anterior segment
- Visual field testing — peripheral field loss in RP (ring scotoma, constricted field), arcuate defects in glaucoma
- Electroretinogram (ERG) — objective measurement of rod and cone photoreceptor function; markedly reduced or extinguished in RP; rod ERG selectively reduced in early VAD
- Serum retinol — plasma retinol <0.70 μmol/L (20 μg/dL) indicates subclinical VAD; <0.35 μmol/L indicates severe deficiency
- Dark adaptation testing — measures the time and final threshold for scotopic sensitivity after light bleaching; delayed dark adaptation and elevated rod thresholds are the functional signature of night blindness from any cause
Treatment: Completely Different
Depending on the Cause
| Cause | Treatment | Outcome | Timeframe |
|---|---|---|---|
| Vitamin A deficiency — functional (XN) | WHO protocol: 200,000 IU Vit A orally on Days 1, 2, 14. For children <1yr: 100,000 IU. Continue dietary improvement: sweet potato, carrots, leafy greens, eggs, liver. | Complete recovery | Days to weeks |
| VAD with Bitot's spots (X1B) | Same supplementation. Bitot's spots may persist for weeks after vitamin A normalisation but are not dangerous themselves. | Full recovery of function | Weeks to months |
| Keratomalacia (X3) — emergency | Immediate high-dose Vit A + antibiotic drops + systemic nutrition support + ophthalmology referral. Fluorescein staining to assess corneal extent. | Permanent scarring likely | Emergency — hours matter |
| Cataract | Cataract surgery with IOL implantation. Night glare/halos may persist with some IOL types (multifocal) even after surgery. | Complete improvement | Immediate post-surgery |
| Uncorrected myopia | Optimal spectacle or contact lens correction. Anti-reflective coating reduces glare. Night driving benefit typically significant. | Substantial improvement | Immediate with correction |
| Glaucoma | IOP control (drops, laser, surgery) slows progression. Visual field loss from established glaucoma is permanent. Low-vision aids for advanced cases. | Stabilisation only | Months of IOP control |
| Retinitis pigmentosa | No cure. Vitamin A palmitate 15,000 IU/day (controversial evidence). Low-vision rehabilitation. UV protection. Gene therapy (Luxturna) for RPE65 mutations only. | Progressive despite treatment | Lifelong monitoring |
| Zinc deficiency (contributing) | Zinc supplementation (20 mg/day for 14 days in children; 25 mg/day for adults) alongside Vitamin A for malnourished patients. More effective than Vit A alone in zinc-deficient populations. | Good when zinc corrected | 2–4 weeks |
Night Driving:
When Night Blindness Becomes a Safety Issue
Night driving is one of the most common complaints that brings night blindness to clinical attention. The specific visual challenges at night that worsen with nyctalopia:
- Reduced contrast sensitivity — faces, pedestrians, and road markings become harder to distinguish
- Glare disability — oncoming headlights cause more intense and prolonged glare; recovery time after glare is extended. This is particularly severe in early cataracts and RP.
- Reduced visual field — RP and advanced glaucoma limit peripheral vision; peripheral pedestrians and cyclists may not be seen
- Delayed dark adaptation — entering a tunnel or poorly lit area causes momentary functional blindness that lasts longer than in normal eyes
In India, there is no formal mandatory vision test for night driving. Motor Vehicles Act requires minimum visual acuity standards for licence grant but does not test scotopic vision or visual field specifically. Ophthalmologists should counsel patients with moderate-severe RP, advanced glaucoma, or severe cataracts about the specific risks of night driving and recommend restriction or cessation where appropriate.
Anti-reflective coatings on spectacle lenses significantly reduce glare for drivers with myopia or after LASIK. Yellow-tinted "night driving" lenses are popular in India but the evidence for their benefit is limited; they may increase contrast slightly but reduce overall light transmission — counterproductive for rod-mediated scotopic vision.
If you have been diagnosed with night blindness, or notice increasing difficulty with night driving: avoid driving after dark until your ophthalmologist has identified and treated the cause. Vitamin A-related night blindness resolves quickly with treatment — you may be able to resume night driving within weeks. RP-related night blindness is progressive; a proactive conversation with your ophthalmologist about when to restrict night driving is important for your safety and that of others. Cataracts respond dramatically to surgery. Inform the RTO of any visual impairment that affects driving ability — this is both a legal and ethical obligation.
Five Questions to Ask
Your Ophthalmologist
-
01"I can't see well at night. Do I need Vitamin A supplements or is something else wrong?"Night blindness always needs formal evaluation before supplementing. If the cause is retinitis pigmentosa, glaucoma, or cataracts, Vitamin A won't help and the real cause will progress untreated. Ask for a dilated fundus examination, visual field test, and serum retinol measurement before starting any supplementation. If the cause is confirmed as VAD, Vitamin A supplementation produces dramatic, rapid improvement — often within a week.
-
02"My child has trouble seeing in the evening. Could this be Vitamin A deficiency?"Possibly — especially if the child has a diet low in dark-green vegetables, carrots, sweet potato, eggs, and dairy; if they've recently had measles or diarrhoea; or if they live in a food-insecure household. Ask your doctor to check for Bitot's spots (foamy conjunctival deposits) — a visible clinical sign of VAD. Check whether the child is receiving Vitamin A supplements under the national programme every 6 months. If VAD is suspected, Vitamin A supplementation should be given promptly without waiting for blood tests in a malnourished child.
-
03"My father was diagnosed with retinitis pigmentosa. What is my risk and should I be tested?"Risk depends on inheritance pattern. If your father has autosomal dominant RP — risk to each child is 50%. Autosomal recessive RP — lower risk to children (unless maternal carrier), but siblings of affected individuals each have 25% risk. X-linked RP — all daughters of an affected man are obligate carriers; sons are unaffected. Ask for a referral to a retinal specialist or genetic counselling service. Genetic testing of the affected family member to identify the causative mutation is the most useful step for family risk assessment.
-
04"I take hydroxychloroquine for rheumatoid arthritis. Can this cause night blindness?"Yes — hydroxychloroquine (and chloroquine) can cause a dose-dependent retinal toxicity (chloroquine/hydroxychloroquine maculopathy) that affects rod and cone function. Night blindness is a symptom of moderate-severe toxicity. The American Academy of Ophthalmology recommends screening ophthalmology examination within 1 year of starting hydroxychloroquine (10-2 visual field, spectral domain OCT, multifocal ERG), and annual screening after 5 years. Inform your ophthalmologist you are on hydroxychloroquine before any eye examination.
-
05"Yellow-tinted night driving glasses — do they actually help?"The evidence does not support yellow-tinted glasses for night driving. Yellow tints do increase contrast for certain stimuli but also reduce total light transmission — the opposite of what scotopic (rod-mediated) vision needs. Studies show they do not reduce reaction time in night driving conditions and may actually worsen it by reducing luminance. Anti-reflective coating on standard clear lenses is more evidence-based for reducing glare from oncoming headlights. If you are struggling with night driving, the priority is diagnosing and treating the underlying cause rather than symptom-masking optical interventions.
Agaaz Ophthalmics in
Night Blindness Diagnosis
Night blindness diagnosis involves a full dilated retinal examination to distinguish VAD, RP, cataracts, and glaucoma. Two Agaaz products are central to this workup.
Distributors, hospitals, and ophthalmic clinics managing general ophthalmology, paediatric eye health, or vision programmes are welcome to contact Agaaz. info@agaaz.life · WhatsApp +91 98241 64173
Night blindness (nyctalopia) is impaired vision in dim light or darkness. It is a symptom, not a disease. Normal night vision depends on rod photoreceptors in the retina, which contain rhodopsin — a pigment that requires Vitamin A to regenerate after light exposure. When Vitamin A is deficient, rhodopsin cannot regenerate and rods fail in low light. Other causes: retinitis pigmentosa (hereditary rod degeneration), cataracts (lens clouding reduces light transmission), glaucoma (peripheral rod loss from optic nerve damage), high myopia (optical defocus in dim light), and medications (chloroquine, anti-epileptics). India's most common cause is Vitamin A deficiency — entirely preventable and reversible with adequate diet or supplementation.
Night blindness from Vitamin A deficiency is cured by foods containing Vitamin A or beta-carotene (converted to Vitamin A in the body). Best foods available in India: (1) Preformed Vitamin A (retinol — highest bioavailability): liver (any animal), eggs, full-fat dairy, ghee; (2) Beta-carotene (provitamin A — bioavailability ~1/6 of retinol): sweet potato/shakarkand, carrot (gajar), dark green leafy vegetables including spinach (palak), methi/fenugreek leaves, drumstick leaves (moringa/sahjan), red palm oil; (3) Fortified foods: certain cooking oils and milk (where FSSAI fortification is implemented). For children with confirmed VAD: Vitamin A supplementation at 200,000 IU (100,000 IU for age 6–11 months) per WHO protocol produces faster recovery than dietary improvement alone and should be given immediately.
It depends entirely on the cause. Night blindness from Vitamin A deficiency: completely curable — oral Vitamin A supplementation reverses rod dysfunction within days to weeks. Night blindness from cataracts: fully curable with cataract surgery. Night blindness from high myopia: substantially improvable with optimal optical correction. Night blindness from retinitis pigmentosa: currently incurable — it is a progressive hereditary disorder. No disease-modifying treatment is available for most RP mutations; Luxturna gene therapy is approved for RPE65 mutations specifically, which represent about 1% of RP cases. Night blindness from glaucoma: partially stabilisable with IOP control; established rod loss is permanent. Night blindness from medication toxicity (chloroquine): may partially recover if the drug is stopped early.
Bitot's spots are foamy, triangular or oval-shaped white to grey deposits on the conjunctiva, typically located at the 3 o'clock and 9 o'clock positions adjacent to the corneal limbus (temporal side most common). They are composed of keratinised epithelial cells and are a clinical sign of Vitamin A deficiency (WHO Stage X1B xerophthalmia). They appear earlier than corneal involvement and can persist for several weeks even after Vitamin A normalises with treatment. They are more common in children with malnutrition. If seen, the child should receive immediate Vitamin A supplementation — they represent established VAD and carry risk of progression to corneal disease if untreated. Bitot's spots can be seen with a torch or during slit-lamp examination.
Yes — and it is a significant public health problem. Vitamin A deficiency is most prevalent in children under 5 and pregnant women in India, particularly in food-insecure rural households. Night blindness in children from VAD is the earliest sign of a deficiency that, if untreated, can progress to Bitot's spots, corneal xerosis, keratomalacia (corneal melting), and permanent blindness. Night blindness in children is a public health sentinel event — its presence in a community indicates underlying severe malnutrition affecting far more children than have visible eye signs. India's national Vitamin A supplementation programme targets children 9–59 months every 6 months; parents should ensure their children receive these doses. Any malnourished child who has difficulty seeing in dim light or evenings should be taken to a doctor immediately.
Both cause night blindness but are completely different conditions. VAD night blindness: caused by inadequate dietary Vitamin A; reversible with supplementation; no structural retinal damage initially; serum retinol low; ERG reducible but recovers; no fundus changes (unless keratomalacia has occurred). Retinitis pigmentosa (RP): hereditary progressive rod-cone degeneration; irreversible; structural loss of rod photoreceptors; ERG markedly reduced or extinguished; characteristic fundus signs (bone-spicule pigmentation, waxy disc pallor, vessel attenuation). Key distinguishing features: RP typically begins in teens-20s in otherwise healthy individuals with adequate diet; positive family history common; visual field progressively constricts; RP does not respond to Vitamin A supplementation (the rods are dying structurally, not functionally impaired by vitamin deficiency).
Diagnosis involves: clinical history (diet, family history, medications, systemic illness), visual acuity and refraction, dilated fundus examination (to identify cataract, RP signs, glaucomatous cupping, retinal vascular changes), slit-lamp examination with fluorescein staining (corneal status, Bitot's spots), visual field testing (RP and glaucoma cause characteristic field defects), electroretinogram (ERG — objective rod/cone function, the definitive test for RP and VAD assessment), serum retinol measurement (plasma retinol <0.70 μmol/L indicates subclinical VAD), and dark adaptation testing (measures final rod threshold and adaptation speed — the direct functional test for night blindness). In a malnourished child in a rural setting with clinical signs of VAD, treatment should not wait for investigations — treat first, confirm later.
Yes — advanced glaucoma causes night blindness through a specific mechanism. Rod photoreceptors are most dense in the peripheral retina. Glaucoma destroys retinal ganglion cells, with peripheral ganglion cells affected first (producing the arcuate scotomas and peripheral field defects that characterise glaucoma). The peripheral rod-rich areas of the retina lose their ganglion cell output in advanced glaucoma, reducing scotopic (dim light) peripheral vision. Patients with advanced glaucoma frequently report difficulty driving at night, navigating in dim environments, and bumping into objects peripherally. This is distinct from the glare issues of cataracts — glaucomatous night blindness is about field loss, not optical scatter. IOP control slows progression but cannot restore already-damaged ganglion cells. Our complete glaucoma guide covers the full management framework.
Yes — zinc deficiency can contribute to or exacerbate night blindness, even when dietary Vitamin A appears adequate. Zinc is required for the synthesis of retinol-binding protein (RBP) in the liver — the transport protein that carries Vitamin A from liver stores to the retina. Without sufficient zinc, Vitamin A may be trapped in the liver and unable to reach the rod cells where it is needed for rhodopsin synthesis. Additionally, zinc is a cofactor for the enzyme alcohol dehydrogenase that converts retinol to retinaldehyde (11-cis-retinal, the rhodopsin chromophore) in the retinal pigment epithelium. Zinc deficiency is common in India, particularly in children with malnutrition — the same population affected by VAD. Studies show that zinc supplementation alongside Vitamin A produces better outcomes for night blindness than Vitamin A alone in zinc-deficient malnourished children.
Yes — night blindness in pregnant women is a recognised marker of Vitamin A deficiency in India and other developing countries. Pregnancy increases Vitamin A requirements because the foetus accumulates Vitamin A from maternal stores, and the mother's own requirements increase. In food-insecure populations, this creates a situation where maternal Vitamin A stores become depleted during pregnancy, impairing rhodopsin regeneration and causing night blindness. Importantly, night blindness in pregnancy is a sentinel public health indicator — its presence signals that Vitamin A deficiency is severe enough to have exceeded the eye's buffering capacity. WHO recommends Vitamin A supplementation for pregnant women with night blindness (up to 10,000 IU/day or 25,000 IU/week — not the high single doses used in children, as high doses carry teratogenicity risk). Night blindness in pregnancy is also associated with increased risk of maternal mortality and child mortality — it is not a trivial symptom.
Research & Citations
Night blindness diagnosis needs
dilated examination.
TRIDILATE (mydriasis for dilated fundus exam) and FLUROSCÉNE (corneal staining for xerophthalmia staging) — Agaaz's diagnostic ophthalmic range. GMP certified. Ahmedabad.
Your Rod Cells Hold One Million
Molecules of Rhodopsin.
Without Vitamin A, They're Useless.
Night blindness is a symptom, not a disease. In India it is usually Vitamin A deficiency — entirely reversible with the right food or a single dose of supplementation. But it can also mean retinitis pigmentosa, glaucoma, or a medication side effect. This is the complete guide to understanding which.
subclinical VAD globally
(adults, ICMR India)
night blindness
prevents it
Night blindness (nyctalopia) is the inability to see well in dim light or darkness. It is a symptom, not a disease. The main causes in India: Vitamin A deficiency (most common, preventable, reversible), retinitis pigmentosa (hereditary, progressive, currently incurable), cataracts, glaucoma, high myopia, and zinc deficiency. Vitamin A is essential for producing rhodopsin — the photopigment in rod cells that enables vision in low light. Without enough Vitamin A, rhodopsin cannot regenerate after light bleaching. Treatment by cause: VAD → oral Vitamin A supplementation (WHO protocol: 200,000 IU age ≥1 year) + dietary improvement (sweet potato, carrots, dark leafy greens, liver, eggs); cataracts → surgery; RP → no cure currently, low-vision aids, vitamin supplementation slows progression. Best preventive foods in India: sweet potato/shakarkand, carrot, drumstick leaves (moringa), spinach, methi, eggs, ghee. Children aged 9–59 months should receive Vitamin A supplements every 6 months under the National Programme.
Rhodopsin: The Only Molecule
Standing Between You and Total Darkness
The human retina contains two types of photoreceptors: approximately 6 million cones — concentrated in the central macula, responsible for colour and fine detail in bright light — and approximately 120 million rods, distributed across the peripheral retina, responsible for low-light (scotopic) vision. At night, in a dimly lit room, or in a cinema, it is almost entirely your rod cells that are working.
Each rod outer segment contains roughly 1,000 disc membranes, each packed with approximately 1,000 molecules of rhodopsin — a G-protein coupled receptor consisting of a protein (opsin) covalently bound to a chromophore (11-cis-retinal). 11-cis-retinal is a derivative of Vitamin A (retinol). When a single photon of light strikes a rhodopsin molecule, 11-cis-retinal isomerises to all-trans-retinal — this conformational change triggers a cascade of G-protein signalling that hyperpolarises the rod cell and transmits a visual signal to the optic nerve.
After bleaching (light exposure), all-trans-retinal must be converted back to 11-cis-retinal to regenerate functional rhodopsin — a process called the visual cycle. This regeneration occurs in the retinal pigment epithelium (RPE) and depends critically on a constant supply of Vitamin A. If Vitamin A is deficient, rhodopsin cannot regenerate after bleaching. The result: rod function is impaired in low light, and the person cannot see in the dark — night blindness.
This is why night blindness from Vitamin A deficiency is fully reversible: replenish the Vitamin A supply, regenerate the rhodopsin, and rod function returns. No permanent structural damage has occurred — unless the deficiency progresses to corneal disease (xerophthalmia, keratomalacia).
ROD vs CONE — SCOTOPIC vs PHOTOPIC VISION COMPARISON
Night blindness is a rod cell problem. Rods contain rhodopsin — the single photopigment that requires Vitamin A. Cones (colour vision, daytime) use different opsins and are largely unaffected by Vitamin A deficiency until severe depletion occurs.
"Rhodopsin constitutes approximately 85% of the total protein content of the rod outer segment disc membrane. Its photoisomerisation by a single photon initiates a signal amplification cascade sufficient to generate a measurable electrical response — this extraordinary sensitivity is what allows the human eye to detect a candle flame at over a mile in darkness, but only if the rhodopsin reservoir is full."
— Adapted from Lamb TD, Pugh EN Jr. "Dark adaptation and the retinoid cycle of vision." Prog Retin Eye Res. 2004.Night Blindness Is a Symptom.
Here Are the Six Things That Cause It.
Vitamin A Deficiency
Rhodopsin cannot regenerate without Vitamin A. Night blindness is the earliest functional sign of VAD — appearing before any structural eye damage. Common in children under 5 and pregnant/lactating women with poor dietary intake. Fully reversible with supplementation.
Retinitis Pigmentosa
Hereditary rod-cone dystrophy: rod cells progressively degenerate. Night blindness is usually the first symptom (teens–30s), followed by progressive peripheral visual field loss, then central vision loss in later stages. Currently incurable. ~1 in 3,000–4,000 people globally.
Cataracts
Lens clouding reduces total light transmission. Pupils dilate in dim light — a cloudy lens in dim light scatters more light proportionally than in bright conditions. Night driving difficulty is a common early cataract symptom. Fully reversible with cataract surgery. See our Cataract Surgery guide.
Glaucoma
Advanced glaucoma destroys peripheral retinal ganglion cells — and rods are densest in the peripheral retina. As glaucoma advances, the scotopic (night) field shrinks before the photopic (day) field because peripheral rod loss reduces dim-light peripheral vision. Night driving restriction is an important quality-of-life issue in advanced glaucoma.
High Myopia
Uncorrected or high myopia reduces the clarity of dim-light images due to retinal defocus. Pupil dilation in dim light increases the diameter of the circle of confusion from an uncorrected refractive error — worsening low-light visual acuity. Correcting myopia (glasses, contact lenses) substantially improves night vision in this group.
Zinc Deficiency
Zinc is required for the synthesis of retinol-binding protein (RBP) in the liver — the transport protein that carries Vitamin A to the retina. In zinc-deficient patients, even adequate dietary Vitamin A may not reach the retina effectively. Zinc deficiency is common in India, particularly in children with malnutrition. Co-supplementation of zinc with Vitamin A improves outcomes better than Vitamin A alone in zinc-deficient populations.
India's Night Blindness:
Preventable. Persistent. Unaddressed.
receiving Vit A supplements (NFHS-5)
prevents night blindness
and mortality risk in children
supplement in national programme
India's National Programme for Prevention and Control of Blindness (NPCB) includes Vitamin A supplementation for children aged 9 months to 5 years — one dose every 6 months. Despite this, NFHS-5 (2019–21) data shows only 59.8% of targeted children received their last supplement dose. In tribal, rural, and low-income urban populations, the coverage gap is wider.
The specific burden in India's context:
- Pregnant women — VAD in pregnant women causes night blindness (a marker of VAD severity) and impairs fetal Vitamin A stores. Night blindness in pregnant women in India is a sentinel indicator for VAD requiring immediate intervention.
- Breastfeeding women — breast milk is the primary Vitamin A source for infants. VAD in lactating mothers means Vitamin A-deficient breast milk, directly transmitting deficiency to the infant.
- Children with diarrhoea or measles — acute illness depletes Vitamin A rapidly. WHO recommends Vitamin A supplementation during measles treatment in developing countries — including India — because measles dramatically worsens VAD and vice versa.
- Malabsorption conditions — Vitamin A is a fat-soluble vitamin; conditions causing fat malabsorption (chronic diarrhoea, celiac disease, biliary obstruction, cystic fibrosis, bariatric surgery) impair Vitamin A absorption regardless of dietary intake.
The 2025 awareness study from Himachal Pradesh confirms the core gap: while 82% of surveyed adults could identify night blindness, only 61.5% knew Vitamin A could prevent it — meaning even people who recognise the condition cannot act on prevention effectively. This awareness gap is the primary target for public health education campaigns.
VITAMIN A SUPPLEMENTATION COVERAGE — INDIA REGIONAL VARIATION (NFHS-5)
Source: NFHS-5 (2019–21), proportion of children 9–59 months who received a Vitamin A supplement in the last 6 months. Significant inter-state variation reflects differential programme implementation and access.
When VAD Gets Worse:
The Xerophthalmia Progression
Night blindness is the earliest functional sign of Vitamin A deficiency — but if the deficiency is not corrected, progressive ocular damage follows. The WHO classifies VAD ocular manifestations using the Xerophthalmia staging system (Sommer, 1982):
XEROPHTHALMIA STAGING — WHO CLASSIFICATION (SOMMER 1982)
Night blindness (XN) is Stage 1. Treatment at this stage produces complete recovery. Keratomalacia (X3) — corneal melting from severe VAD — causes permanent scarring and blindness. Bitot's spots (X1B) are foamy, triangular conjunctival deposits adjacent to the limbus — a classic clinical sign of VAD, visible at the slit lamp or with a torch.
X3 xerophthalmia (keratomalacia) — corneal softening and necrosis from severe prolonged VAD — is a medical emergency. A malnourished child presenting with keratomalacia requires immediate high-dose Vitamin A (200,000 IU orally on Day 1, Day 2, and Day 14 per WHO protocol) plus systemic nutritional support, antibiotic eye drops, and urgent ophthalmology referral. Corneal perforation can occur within hours in severe cases. Permanent corneal scarring and blindness result even with treatment at this stage. Any paediatric patient with measles, diarrhoea, or malnutrition and corneal signs should be treated presumptively for VAD immediately — do not wait for serum retinol results.
How Much Vitamin A
Are You Actually Getting Today?
When Night Blindness Is Not Vitamin A:
Retinitis Pigmentosa
Retinitis pigmentosa (RP) is a group of inherited retinal dystrophies characterised by progressive rod photoreceptor degeneration, followed by cone degeneration. It is the most common hereditary cause of blindness, affecting approximately 1 in 3,500–4,000 people globally — and is the dominant cause of non-nutritional night blindness in India.
RP presents as a clinical triad:
- Night blindness — typically the first symptom, appearing in the second or third decade of life. Rod cells in the peripheral retina degenerate first, so dim-light and peripheral vision are initially affected.
- Progressive peripheral visual field loss — "tunnel vision." As rods continue to die, the visual field constricts from the periphery inward. At advanced stages, the patient may have central vision only, as if looking through a narrow tube.
- Eventual central vision loss — as cone degeneration follows rod degeneration in later stages, central visual acuity also declines. Full blindness occurs in some but not all patients.
On examination, the classic fundus signs of RP include:
- Bone-spicule pigmentation in the mid-peripheral retina — dark, branching pigment deposits resembling bone spicules on slit-lamp biomicroscopy
- Waxy pallor of the optic disc
- Attenuation of retinal blood vessels
- Reduced or extinguished ERG (electroretinogram) — the definitive diagnostic test
Genetics: RP can be autosomal dominant (ADRP), autosomal recessive (ARRP), or X-linked (XLRP — most severe, affects males, carrier females sometimes symptomatic). Over 80 causative genes have been identified. In India, consanguineous marriages (particularly in some communities) increase the prevalence of autosomal recessive RP.
Management: Currently, there is no approved cure for most forms of RP. Vitamin A palmitate supplementation (15,000 IU/day) has shown modest slowing of ERG decline in some trials (Berson et al., 1993) but remains controversial. Luxturna (voretigene neparvovec) — an AAV2-mediated gene therapy for RPE65 mutation-associated retinal dystrophy — is approved and available, but RPE65 mutations represent only ~1% of RP cases. Low-vision rehabilitation, orientation and mobility training, and adaptive technology are the primary support for most RP patients. Bright light avoidance and UV-protective spectacles are recommended to slow cone degeneration. Regular retinal follow-up is essential.
What the Doctor Finds:
From Torch to Electroretinogram
Night blindness diagnosis begins with distinguishing between the common, reversible causes (Vitamin A deficiency, cataracts, uncorrected myopia) and the rarer but serious hereditary and structural causes (RP, advanced glaucoma, medication toxicity). The workup:
- Clinical history — onset (sudden vs gradual), age, family history of night blindness or blindness, dietary history (VAD risk factors), medications (chloroquine, hydroxychloroquine, anti-epileptics), systemic conditions (malabsorption, bariatric surgery, IBD)
- Visual acuity and refraction — uncorrected myopia as a contributing factor
- Dilated fundus examination with TRIDILATE — to assess the lens (cataract), optic disc (glaucoma, RP pallor), macula (AMD, chorioretinal atrophy), and peripheral retina (RP bone-spicule pigmentation, choroidal changes)
- Slit-lamp examination with FLUROSCÉNE strips for corneal staining — evaluating corneal status (xerosis, Bitot spots, early keratomalacia), conjunctival xerosis, and anterior segment
- Visual field testing — peripheral field loss in RP (ring scotoma, constricted field), arcuate defects in glaucoma
- Electroretinogram (ERG) — objective measurement of rod and cone photoreceptor function; markedly reduced or extinguished in RP; rod ERG selectively reduced in early VAD
- Serum retinol — plasma retinol <0.70 μmol/L (20 μg/dL) indicates subclinical VAD; <0.35 μmol/L indicates severe deficiency
- Dark adaptation testing — measures the time and final threshold for scotopic sensitivity after light bleaching; delayed dark adaptation and elevated rod thresholds are the functional signature of night blindness from any cause
Treatment: Completely Different
Depending on the Cause
| Cause | Treatment | Outcome | Timeframe |
|---|---|---|---|
| Vitamin A deficiency — functional (XN) | WHO protocol: 200,000 IU Vit A orally on Days 1, 2, 14. For children <1yr: 100,000 IU. Continue dietary improvement: sweet potato, carrots, leafy greens, eggs, liver. | Complete recovery | Days to weeks |
| VAD with Bitot's spots (X1B) | Same supplementation. Bitot's spots may persist for weeks after vitamin A normalisation but are not dangerous themselves. | Full recovery of function | Weeks to months |
| Keratomalacia (X3) — emergency | Immediate high-dose Vit A + antibiotic drops + systemic nutrition support + ophthalmology referral. Fluorescein staining to assess corneal extent. | Permanent scarring likely | Emergency — hours matter |
| Cataract | Cataract surgery with IOL implantation. Night glare/halos may persist with some IOL types (multifocal) even after surgery. | Complete improvement | Immediate post-surgery |
| Uncorrected myopia | Optimal spectacle or contact lens correction. Anti-reflective coating reduces glare. Night driving benefit typically significant. | Substantial improvement | Immediate with correction |
| Glaucoma | IOP control (drops, laser, surgery) slows progression. Visual field loss from established glaucoma is permanent. Low-vision aids for advanced cases. | Stabilisation only | Months of IOP control |
| Retinitis pigmentosa | No cure. Vitamin A palmitate 15,000 IU/day (controversial evidence). Low-vision rehabilitation. UV protection. Gene therapy (Luxturna) for RPE65 mutations only. | Progressive despite treatment | Lifelong monitoring |
| Zinc deficiency (contributing) | Zinc supplementation (20 mg/day for 14 days in children; 25 mg/day for adults) alongside Vitamin A for malnourished patients. More effective than Vit A alone in zinc-deficient populations. | Good when zinc corrected | 2–4 weeks |
Night Driving:
When Night Blindness Becomes a Safety Issue
Night driving is one of the most common complaints that brings night blindness to clinical attention. The specific visual challenges at night that worsen with nyctalopia:
- Reduced contrast sensitivity — faces, pedestrians, and road markings become harder to distinguish
- Glare disability — oncoming headlights cause more intense and prolonged glare; recovery time after glare is extended. This is particularly severe in early cataracts and RP.
- Reduced visual field — RP and advanced glaucoma limit peripheral vision; peripheral pedestrians and cyclists may not be seen
- Delayed dark adaptation — entering a tunnel or poorly lit area causes momentary functional blindness that lasts longer than in normal eyes
In India, there is no formal mandatory vision test for night driving. Motor Vehicles Act requires minimum visual acuity standards for licence grant but does not test scotopic vision or visual field specifically. Ophthalmologists should counsel patients with moderate-severe RP, advanced glaucoma, or severe cataracts about the specific risks of night driving and recommend restriction or cessation where appropriate.
Anti-reflective coatings on spectacle lenses significantly reduce glare for drivers with myopia or after LASIK. Yellow-tinted "night driving" lenses are popular in India but the evidence for their benefit is limited; they may increase contrast slightly but reduce overall light transmission — counterproductive for rod-mediated scotopic vision.
If you have been diagnosed with night blindness, or notice increasing difficulty with night driving: avoid driving after dark until your ophthalmologist has identified and treated the cause. Vitamin A-related night blindness resolves quickly with treatment — you may be able to resume night driving within weeks. RP-related night blindness is progressive; a proactive conversation with your ophthalmologist about when to restrict night driving is important for your safety and that of others. Cataracts respond dramatically to surgery. Inform the RTO of any visual impairment that affects driving ability — this is both a legal and ethical obligation.
Five Questions to Ask
Your Ophthalmologist
-
01"I can't see well at night. Do I need Vitamin A supplements or is something else wrong?"Night blindness always needs formal evaluation before supplementing. If the cause is retinitis pigmentosa, glaucoma, or cataracts, Vitamin A won't help and the real cause will progress untreated. Ask for a dilated fundus examination, visual field test, and serum retinol measurement before starting any supplementation. If the cause is confirmed as VAD, Vitamin A supplementation produces dramatic, rapid improvement — often within a week.
-
02"My child has trouble seeing in the evening. Could this be Vitamin A deficiency?"Possibly — especially if the child has a diet low in dark-green vegetables, carrots, sweet potato, eggs, and dairy; if they've recently had measles or diarrhoea; or if they live in a food-insecure household. Ask your doctor to check for Bitot's spots (foamy conjunctival deposits) — a visible clinical sign of VAD. Check whether the child is receiving Vitamin A supplements under the national programme every 6 months. If VAD is suspected, Vitamin A supplementation should be given promptly without waiting for blood tests in a malnourished child.
-
03"My father was diagnosed with retinitis pigmentosa. What is my risk and should I be tested?"Risk depends on inheritance pattern. If your father has autosomal dominant RP — risk to each child is 50%. Autosomal recessive RP — lower risk to children (unless maternal carrier), but siblings of affected individuals each have 25% risk. X-linked RP — all daughters of an affected man are obligate carriers; sons are unaffected. Ask for a referral to a retinal specialist or genetic counselling service. Genetic testing of the affected family member to identify the causative mutation is the most useful step for family risk assessment.
-
04"I take hydroxychloroquine for rheumatoid arthritis. Can this cause night blindness?"Yes — hydroxychloroquine (and chloroquine) can cause a dose-dependent retinal toxicity (chloroquine/hydroxychloroquine maculopathy) that affects rod and cone function. Night blindness is a symptom of moderate-severe toxicity. The American Academy of Ophthalmology recommends screening ophthalmology examination within 1 year of starting hydroxychloroquine (10-2 visual field, spectral domain OCT, multifocal ERG), and annual screening after 5 years. Inform your ophthalmologist you are on hydroxychloroquine before any eye examination.
-
05"Yellow-tinted night driving glasses — do they actually help?"The evidence does not support yellow-tinted glasses for night driving. Yellow tints do increase contrast for certain stimuli but also reduce total light transmission — the opposite of what scotopic (rod-mediated) vision needs. Studies show they do not reduce reaction time in night driving conditions and may actually worsen it by reducing luminance. Anti-reflective coating on standard clear lenses is more evidence-based for reducing glare from oncoming headlights. If you are struggling with night driving, the priority is diagnosing and treating the underlying cause rather than symptom-masking optical interventions.
Agaaz Ophthalmics in
Night Blindness Diagnosis
Night blindness diagnosis involves a full dilated retinal examination to distinguish VAD, RP, cataracts, and glaucoma. Two Agaaz products are central to this workup.
Distributors, hospitals, and ophthalmic clinics managing general ophthalmology, paediatric eye health, or vision programmes are welcome to contact Agaaz. info@agaaz.life · WhatsApp +91 98241 64173
Night blindness (nyctalopia) is impaired vision in dim light or darkness. It is a symptom, not a disease. Normal night vision depends on rod photoreceptors in the retina, which contain rhodopsin — a pigment that requires Vitamin A to regenerate after light exposure. When Vitamin A is deficient, rhodopsin cannot regenerate and rods fail in low light. Other causes: retinitis pigmentosa (hereditary rod degeneration), cataracts (lens clouding reduces light transmission), glaucoma (peripheral rod loss from optic nerve damage), high myopia (optical defocus in dim light), and medications (chloroquine, anti-epileptics). India's most common cause is Vitamin A deficiency — entirely preventable and reversible with adequate diet or supplementation.
Night blindness from Vitamin A deficiency is cured by foods containing Vitamin A or beta-carotene (converted to Vitamin A in the body). Best foods available in India: (1) Preformed Vitamin A (retinol — highest bioavailability): liver (any animal), eggs, full-fat dairy, ghee; (2) Beta-carotene (provitamin A — bioavailability ~1/6 of retinol): sweet potato/shakarkand, carrot (gajar), dark green leafy vegetables including spinach (palak), methi/fenugreek leaves, drumstick leaves (moringa/sahjan), red palm oil; (3) Fortified foods: certain cooking oils and milk (where FSSAI fortification is implemented). For children with confirmed VAD: Vitamin A supplementation at 200,000 IU (100,000 IU for age 6–11 months) per WHO protocol produces faster recovery than dietary improvement alone and should be given immediately.
It depends entirely on the cause. Night blindness from Vitamin A deficiency: completely curable — oral Vitamin A supplementation reverses rod dysfunction within days to weeks. Night blindness from cataracts: fully curable with cataract surgery. Night blindness from high myopia: substantially improvable with optimal optical correction. Night blindness from retinitis pigmentosa: currently incurable — it is a progressive hereditary disorder. No disease-modifying treatment is available for most RP mutations; Luxturna gene therapy is approved for RPE65 mutations specifically, which represent about 1% of RP cases. Night blindness from glaucoma: partially stabilisable with IOP control; established rod loss is permanent. Night blindness from medication toxicity (chloroquine): may partially recover if the drug is stopped early.
Bitot's spots are foamy, triangular or oval-shaped white to grey deposits on the conjunctiva, typically located at the 3 o'clock and 9 o'clock positions adjacent to the corneal limbus (temporal side most common). They are composed of keratinised epithelial cells and are a clinical sign of Vitamin A deficiency (WHO Stage X1B xerophthalmia). They appear earlier than corneal involvement and can persist for several weeks even after Vitamin A normalises with treatment. They are more common in children with malnutrition. If seen, the child should receive immediate Vitamin A supplementation — they represent established VAD and carry risk of progression to corneal disease if untreated. Bitot's spots can be seen with a torch or during slit-lamp examination.
Yes — and it is a significant public health problem. Vitamin A deficiency is most prevalent in children under 5 and pregnant women in India, particularly in food-insecure rural households. Night blindness in children from VAD is the earliest sign of a deficiency that, if untreated, can progress to Bitot's spots, corneal xerosis, keratomalacia (corneal melting), and permanent blindness. Night blindness in children is a public health sentinel event — its presence in a community indicates underlying severe malnutrition affecting far more children than have visible eye signs. India's national Vitamin A supplementation programme targets children 9–59 months every 6 months; parents should ensure their children receive these doses. Any malnourished child who has difficulty seeing in dim light or evenings should be taken to a doctor immediately.
Both cause night blindness but are completely different conditions. VAD night blindness: caused by inadequate dietary Vitamin A; reversible with supplementation; no structural retinal damage initially; serum retinol low; ERG reducible but recovers; no fundus changes (unless keratomalacia has occurred). Retinitis pigmentosa (RP): hereditary progressive rod-cone degeneration; irreversible; structural loss of rod photoreceptors; ERG markedly reduced or extinguished; characteristic fundus signs (bone-spicule pigmentation, waxy disc pallor, vessel attenuation). Key distinguishing features: RP typically begins in teens-20s in otherwise healthy individuals with adequate diet; positive family history common; visual field progressively constricts; RP does not respond to Vitamin A supplementation (the rods are dying structurally, not functionally impaired by vitamin deficiency).
Diagnosis involves: clinical history (diet, family history, medications, systemic illness), visual acuity and refraction, dilated fundus examination (to identify cataract, RP signs, glaucomatous cupping, retinal vascular changes), slit-lamp examination with fluorescein staining (corneal status, Bitot's spots), visual field testing (RP and glaucoma cause characteristic field defects), electroretinogram (ERG — objective rod/cone function, the definitive test for RP and VAD assessment), serum retinol measurement (plasma retinol <0.70 μmol/L indicates subclinical VAD), and dark adaptation testing (measures final rod threshold and adaptation speed — the direct functional test for night blindness). In a malnourished child in a rural setting with clinical signs of VAD, treatment should not wait for investigations — treat first, confirm later.
Yes — advanced glaucoma causes night blindness through a specific mechanism. Rod photoreceptors are most dense in the peripheral retina. Glaucoma destroys retinal ganglion cells, with peripheral ganglion cells affected first (producing the arcuate scotomas and peripheral field defects that characterise glaucoma). The peripheral rod-rich areas of the retina lose their ganglion cell output in advanced glaucoma, reducing scotopic (dim light) peripheral vision. Patients with advanced glaucoma frequently report difficulty driving at night, navigating in dim environments, and bumping into objects peripherally. This is distinct from the glare issues of cataracts — glaucomatous night blindness is about field loss, not optical scatter. IOP control slows progression but cannot restore already-damaged ganglion cells. Our complete glaucoma guide covers the full management framework.
Yes — zinc deficiency can contribute to or exacerbate night blindness, even when dietary Vitamin A appears adequate. Zinc is required for the synthesis of retinol-binding protein (RBP) in the liver — the transport protein that carries Vitamin A from liver stores to the retina. Without sufficient zinc, Vitamin A may be trapped in the liver and unable to reach the rod cells where it is needed for rhodopsin synthesis. Additionally, zinc is a cofactor for the enzyme alcohol dehydrogenase that converts retinol to retinaldehyde (11-cis-retinal, the rhodopsin chromophore) in the retinal pigment epithelium. Zinc deficiency is common in India, particularly in children with malnutrition — the same population affected by VAD. Studies show that zinc supplementation alongside Vitamin A produces better outcomes for night blindness than Vitamin A alone in zinc-deficient malnourished children.
Yes — night blindness in pregnant women is a recognised marker of Vitamin A deficiency in India and other developing countries. Pregnancy increases Vitamin A requirements because the foetus accumulates Vitamin A from maternal stores, and the mother's own requirements increase. In food-insecure populations, this creates a situation where maternal Vitamin A stores become depleted during pregnancy, impairing rhodopsin regeneration and causing night blindness. Importantly, night blindness in pregnancy is a sentinel public health indicator — its presence signals that Vitamin A deficiency is severe enough to have exceeded the eye's buffering capacity. WHO recommends Vitamin A supplementation for pregnant women with night blindness (up to 10,000 IU/day or 25,000 IU/week — not the high single doses used in children, as high doses carry teratogenicity risk). Night blindness in pregnancy is also associated with increased risk of maternal mortality and child mortality — it is not a trivial symptom.
Research & Citations
Night blindness diagnosis needs
dilated examination.
TRIDILATE (mydriasis for dilated fundus exam) and FLUROSCÉNE (corneal staining for xerophthalmia staging) — Agaaz's diagnostic ophthalmic range. GMP certified. Ahmedabad.
Night Blindness: Vitamin A, Causes & Treatment India 2026